News
RVMDW
9.33
+5.37%
0.48
Weekly Report: what happened at RVMDW last week (1019-1023)?
Weekly Report · 2d ago
Weekly Report: what happened at RVMDW last week (1012-1016)?
Weekly Report · 10/19 10:27
Weekly Report: what happened at RVMDW last week (1005-1009)?
Weekly Report · 10/12 10:33
Weekly Report: what happened at RVMDW last week (0928-1002)?
Weekly Report · 10/05 10:32
Weekly Report: what happened at RVMDW last week (0921-0925)?
Weekly Report · 09/28 10:27
Weekly Report: what happened at RVMDW last week (0914-0918)?
Weekly Report · 09/21 10:27
Weekly Report: what happened at RVMDW last week (0907-0911)?
Weekly Report · 09/14 10:33
IHE: Innovation Supports The Outlook, Valuation Limits Conviction
Seeking Alpha · 09/11 17:54
Weekly Report: what happened at RVMDW last week (0831-0904)?
Weekly Report · 09/07 10:25
Weekly Report: what happened at RVMDW last week (0824-0828)?
Weekly Report · 08/31 10:34
Revolution Medicines: Strong Buy RASONQUE FDA Approval And Zoldonrasib PDAC Expansions
Seeking Alpha · 08/31 03:39
Weekly Report: what happened at RVMDW last week (0817-0821)?
Weekly Report · 08/24 10:34
Weekly Report: what happened at RVMDW last week (0810-0814)?
Weekly Report · 08/17 10:35
Weekly Report: what happened at RVMDW last week (0803-0807)?
Weekly Report · 08/10 10:29
Weekly Report: what happened at RVMDW last week (0727-0731)?
Weekly Report · 08/03 10:29
Weekly Report: what happened at RVMDW last week (0720-0724)?
Weekly Report · 07/27 10:34
Weekly Report: what happened at RVMDW last week (0713-0717)?
Weekly Report · 07/20 10:30
Weekly Report: what happened at RVMDW last week (0706-0710)?
Weekly Report · 07/13 10:32
Weekly Report: what happened at RVMDW last week (0629-0703)?
Weekly Report · 07/06 10:37
Weekly Report: what happened at RVMDW last week (0622-0626)?
Weekly Report · 06/29 10:30
More
Webull provides a variety of real-time RVMDW stock news. You can receive the latest news about Revolution through multiple platforms. This information may help you make smarter investment decisions.
About RVMDW
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company’s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.